Racial differences in renal vascular response to angiotensin blockade with captopril or candesartan

Journal of Hypertension

Volumn 25, Issue 4, 2007, Pages 877-882

  Forman, John P ^a,b   Price, Deborah A ^a   Stevanovic, Radomir ^a   Fisher, Naomi D L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CHANNING LABORATORY   (United States)

Author keywords

Angiotensin; Angiotensin converting enzyme inhibition; Ethnicity; Renal hemodynamics

Indexed keywords

ANGIOTENSIN; CANDESARTAN; CAPTOPRIL;

ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; CAUCASIAN; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; MALE; NEGRO; NORMAL HUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; RECEPTOR BLOCKING; SODIUM BALANCE;

EID: 33947179463     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32803cae1a     Document Type: Article

References (40)

1. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997; 277:1293-1298.
2. Price DA, Fisher ND. The renin-angiotensin system in blacks: active, passive, or what? Curr Hypertens Rep 2003; 5:225-230.
3. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163:525-541.
4. Price DA, De'Oliveira JM, Fisher ND, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997; 30:240-246.
5. Price DA, Porter LE, Gordon M, Fisher ND, De'Oliveira JM, Laffel LM, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10:2382-2391.
6. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest 1983; 72:2115-2124.
7. Price DA, Fisher ND, Osei SY, Lansang MC, Hollenberg NK. Renal perfusion and function in healthy African Americans. Kidney Int 2001; 59:1037-1043.
8. Hollenberg NK, Meggs LG, Williams GH, Katz J, Garnic JD, Harrington DP. Sodium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int 1981; 20:240-245.
9. Miura S, Ideishi M, Sakai T, Motoyama M, Kinoshita A, Sasaguri M, et al. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens 1994; 12:1177-1181.
10. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32:387-392.
11. Hollenberg NK, Osei SY, Lansang MC, Price DA, Fisher ND. Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. J Renin Angiotensin Aldosterone Syst 2001; 2:14-18.
12. Hollenberg NK, Fisher ND. Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hypertension 1995; 26:602-609.
13. Lansang MC, Osei SY, Price DA, Fisher ND, Hollenberg NK. Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan. Hypertension 2000; 36:834-838.
14. Hopkins PN, Hunt SC, Jeunemaitre X, Smith B, Solorio D, Fisher ND, et al. Angiotensinogen genotype affects renal and adrenal responses to angiotensin II in essential hypertension. Circulation 2002; 105:1921-1927.
15. Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension 2005; 46:1316-1320.
16. Hopkins PN, Lifton RP, Hollenberg NK, Jeunemaitre X, Hallouin MC, Skuppin J, et al. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens 1996; 14:199-207.
17. Price DA, Lansang MC, Osei SY, Fisher ND, Laffel LM, Hollenberg NK. Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan. Diabet Med 2002; 19:858-861.
18. Price DA, Fisher ND, Lansang MC, Stevanovic R, Williams GH, Hollenberg NK. Renal perfusion in blacks: alterations caused by insuppressibility of intrarenal renin with salt. Hypertension 2002; 40:186-189.
19. Pappoe LS, Ahmed SB, Fisher ND, Hollenberg NK. Obesity, ethnicity and the renal response to ACE inhibition. New York: American Society for Hypertension; 2006.
20. Rayner BL, Myers JE, Opie LH, Trinder YA, Davidson JS. Screening for primary aldosteronism - normal ranges for aldosterone and renin in three South African population groups. S Afr Med J 2001; 91:594-599.
21. Levy SB, Lilley JJ, Frigon RP, Stone RA. Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake. J Clin Invest 1977; 60:129-138.
22. Drummond Pecly IM, Genelhu De Abreu Fagundes V, Francischetti EA. A definite role for the kallikrein-kinin system in the renal hemodynamic response to an oral protein load during the aging process. Nephron 1999; 83:308-313.
23. Holland OB, Chud JM, Braunstein H. Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J Clin Invest 1980; 65:347-356.
24. Burkhart DG, Brown NJ, Griffin MR, Ray WA, Hammerstrom T, Weiss S. Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. Pharmacoepidemiol Drug Saf 1996; 5:149-154.
25. Gainer JV, Nadeau JH, Ryder D, Brown NJ. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 1996; 98:283-287.
26. Fisher ND, Price DA, Litchfield WR, Williams GH, Hollenberg NK. Renal response to captopril reflects state of local renin system in healthy humans. Kidney Int 1999; 56:635-641.
27. Hollenberg NK, Passan DR. Specificity of renal vasodilation with captopril: saralasin prevents the response in the DOCA-treated, salt-loaded rabbit. Life Sci 1982; 31:329-334.
28. Li T, Zimmerman BG. Relation between inhibition of renal angiotensin II production and hemodynamic effect of captopril in anesthetized rabbit. J Hypertens 1992; 10:795-805.
29. Steckelings UM, Kaschina E, Unger T. The AT2 receptor - a matter of love and hate. Peptides 2005; 26:1401-1409.
30. Ferrario CM, Chappell MC, Dean RH, Iyer SN. Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. J Am Soc Nephrol 1998; 9:1716-1722.
31. Yu N, Chen FC, Ota S, Jorde LB, Pamilo P, Patthy L, et al. Larger genetic differences within africans than between Africans and Eurasians. Genetics 2002; 161:269-274.
32. Hill AV, Allsopp CE, Kwiatkowski D, Taylor TE, Yates SN, Anstey NM, et al. Extensive genetic diversity in the HLA class II region of Africans, with a focally predominant allele, DRB1*1304. Proc Natl Acad Sci U S A 1992; 89:2277-2281.
33. Price DA, Crook ED. Kidney disease in African Americans: genetic considerations. J Natl Med Assoc 2002; 94:16S-27S.
34. Yu H, Song Q, Freedman BI, Chao J, Chao L, Rich SS, Bowden DW. Association of the tissue kallikrein gene promoter with ESRD and hypertension. Kidney Int 2002; 61:1030-1039.
35. Slim R, Torremocha F, Moreau T, Pizard A, Hunt SC, Vuagnat A, et al. Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J Am Soc Nephrol 2002; 13:968-976.
36. Tanus-Santos JE, Desai M, Flockhart DA. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 2001; 11:719-725.
37. Hooper WC, Lally C, Austin H, Benson J, Dilley A, Wenger NK, et al. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans. Chest 1999; 116:880-886.
38. Marroni AS, Metzger IF, Souza-Costa DC, Nagassaki S, Sandrim VC, Correa RX, et al. Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide 2005; 12:177-182.
39. Fisher ND, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension 1994; 23:44-51.
40. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295:1549-1555.